SciELO - Scientific Electronic Library Online

 
vol.120 issue3-4Automatic classification of social media reports on violent incidents in South Africa using machine learningResearch productivity in science and its relationship to race in South Africa author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • On index processSimilars in Google

Share


South African Journal of Science

On-line version ISSN 1996-7489
Print version ISSN 0038-2353

Abstract

DU PLESSIS, Manisha; FOURIE, Carla; LE ROUX, Heloise  and  ENGELBRECHT, Anna-Mart. Sanguinarine highly sensitises breast cancer cells to doxorubicin-induced apoptosis. S. Afr. j. sci. [online]. 2024, vol.120, n.3-4, pp.1-12. ISSN 1996-7489.  http://dx.doi.org/10.17159/sajs.2024/14917.

Breast cancer is the most commonly diagnosed cancer and the second most common cause of cancer death in women. The anthracycline, doxorubicin, is a well-known and highly effective treatment for breast cancer patients; however, many patients present with resistance to chemotherapeutic drugs, which ultimately results in treatment failure and contributes to high mortality rates. It is well established that the mitogen-activated protein kinase phosphatase 1 (MKP-1) mediates the response to chemotherapy, where upregulated MKP-1 is associated with chemoresistance. We investigated whether MKP-1 inhibition or silencing can sensitise triple-negative MDA-MB-231 breast cancer cells to doxorubicin therapy. We found that MKP-1 inhibition and silencing sensitises breast cancer cells to doxorubicin-induced apoptosis. Additionally, the inhibition of MKP-1 in combination with doxorubicin treatment promotes autophagy induction, while doxorubicin and not MKP-1 modulation increased lysosomal acidic compartments. As such, this study demonstrated that MKP-1 inhibition has a potential therapeutic benefit for breast cancer patients by increasing the efficacy of conventional chemotherapy. Therefore, MKP-1 inhibition should be developed as a clinically relevant adjuvant therapy, which could provide a novel avenue for therapeutic intervention in combination with chemotherapy in breast cancer patients. SIGNIFICANCE: • MKP-1 inhibition with sanguinarine and silencing sensitises breast cancer cells to doxorubicin-induced apoptosis. • The inhibition of MKP-1 with sanguinarine in combination with doxorubicin treatment promotes autophagy induction. • MKP-1 inhibition can have a potential therapeutic benefit for breast cancer patients by increasing the efficacy of conventional chemotherapy.

Keywords : breast cancer; MKP-1; doxorubicin; MAPKs; autophagy; apoptosis.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License